Agios Pharmaceuticals Inc
AGIO
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.93B
Close$
$-9.60
128.1% downside
Current Fair Value
128.1% downsideOvervalued by 128.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.93 Billion |
|---|---|
| Enterprise Value | $1.86 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-7.12 |
| Beta | 0.54 |
| Outstanding Shares | 59,488,871 |
Return
| Return on Equity | -40.09% |
|---|---|
| Return on Assets | -37.11% |
| Return on Invested Capital | -44.21% |
Valuation & Multiples
| P/E Ratio | -4.6 |
|---|---|
| PEG | 45.57 |
| Price to Sales | 34.21 |
| Price to Book Ratio | 2.01 |
| Enterprise Value to Revenue | 18.9 |
| Enterprise Value to EBIT | -4.05 |
| Enterprise Value to Net Income | -5 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 30, 2026
EPS Estimate
$-1.65
Average shareholder expectationRevenue Estimate
$26.40 M
Average shareholder expectationNext Earnings Call
Expected Date
October 29, 2026
EPS Estimate
$-1.26
Average shareholder expectationRevenue Estimate
$53.80 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 1.0000▲ 89.23% |
|---|---|
| Total Calls | 33,000▼ 99.10% |
| Total Puts | 33,000▼ 91.61% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 24.66%▼ 82.58% |
|---|---|
| Total Invested | $540.10M▼ 74.52% |
| Investors Holding | 78▼ 170.00% |
ESG Score
No data
About Agios Pharmaceuticals Inc
536 employees
CEO: Jacqualyn Fouse Agios Pharmaceuticals Inc. is a public American pharmaceutical company focused on developing small-molecule anti-cancer therapeutics targeting cancer cell metabolism via the growth factor pathway. Among the proteins under investigation b...